Abstract: An electronic device is provided. The electronic device includes: a back plate, a panel, a first support component and a second support component. The panel is disposed on the back plate and includes a first corner and a second corner. The first support component is disposed between the first corner of the panel and the back plate. The second support component is disposed between the second corner of the panel and the back plate. At least one of the first support component and the second support component has a slot, and a first portion of the back plate extends into the slot.

Abstract: An extension socket includes a shell, a connecting wire, a wire box, a rotating shaft and a take-up reel. An electric connecting socket being formed in the shell, and a side wall of the shell being surrounded to form a first accommodating cavity. The electric connecting wire being electrically connected with the electric connecting socket. The wire box being arranged in the first accommodating cavity, and a side wall of the wire box being surrounded to form a second accommodating cavity. The rotating shaft being connected to an inner wall of the wire box. And the take-up reel being arranged in the second accommodating cavity and rotatably connected with the rotating shaft, and the take-up reel being used for winding the electric connecting wire.

Abstract: In certain aspects, a three-dimensional (3D) memory device includes a stack structure including interleaved conductive layers and dielectric layers and having a core array region and a staircase region in a plan view, one or more channel structures each extending through the core array region of the stack structure, and one or more contact structures each extending through the stack structure, wherein each of the one or more contact structures includes a head portion and a body portion, and a width of the head portion of the respective contact structure is larger than that of the body portion of the respective contact structure.

Abstract: An intelligent plate parts machining production line combining universal equipment and special equipment. Four special machining tools are located on first to fourth stations, respectively, and a universal machining tool is located on a fifth station. The stations are sequential from an automatic feeding device. Truss conveying devices are behind the first to fourth stations, and four mechanical arms are on the truss conveying devices. A four-axis manipulator is between the fourth and fifth stations for transferring materials between the two stations and discharging finished products. Industrial cameras are on the second-station mechanical arm and the four-axis manipulator. Waste boxes are between the first and second stations and between the fourth and fifth stations. A discharging box is on the front side of the fifth station. A scrap conveying mechanism is below the production line. Flexible clamps and sliding rail cylinders are used, so that the production line is flexible.

Abstract: An intelligent plate parts machining production line combining universal equipment and special equipment. Four special machining tools are located on first to fourth stations, respectively, and a universal machining tool is located on a fifth station. The stations are sequential from an automatic feeding device. Truss conveying devices are behind the first to fourth stations, and four mechanical arms are on the truss conveying devices. A four-axis manipulator is between the fourth and fifth stations for transferring materials between the two stations and discharging finished products. Industrial cameras are on the second-station mechanical arm and the four-axis manipulator. Waste boxes are between the first and second stations and between the fourth and fifth stations. A discharging box is on the front side of the fifth station. A scrap conveying mechanism is below the production line. Flexible clamps and sliding rail cylinders are used, so that the production line is flexible.

Abstract: Disclosed arc compositions, methods, and kits for treating a solid tumor comprising co- administering to an individual in need thereof a BTK inhibitor and an mTOR inhibitor: a taxane, or an EGFR inhibitor.

Abstract: Disclosed are compositions, methods, and kits for treating a solid tumor comprising co-administering to an individual in need thereof a BTK inhibitor and an mTOR inhibitor; a taxane, or an EGFR inhibitor.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudo-virus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudo-viruses (VLPs with plasmids inside). Oral administration of the pseudo-viruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudo-virus induces stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body.

Abstract: The invention involves a papilloma pseudo-virus that can induce immune response after oral intake as well as its preparation. It characterizes that: the HPV or BPV pseudo-virus made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), reassembled into pseudo-virus (VLPs with plasmids inside). The pseudo-virus can be orally given, entering mucosa and systemic lymphoid tissues of human body, activate immune system and serve as treating and preventing agent. The pseudo-virus can induce stronger immune response than DNA vaccines. Additionally, the pseudo-virus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in human body.